Compare McKesson Corporation (MCK) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Global X Uranium ETF — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Global X Uranium ETF trades at $39.16. The key difference: McKesson Corporation pays a 0.39% dividend while Global X Uranium ETF pays none, and McKesson Corporation is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| MCK | URA | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $995.69 | $61.81 |
52-Week Low | $659.01 | $36.45 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend but oversold oscillators suggesting potential for a rebound. The fund's positioning in uranium and nuclear energy is buoyed by long-term demand drivers including AI power needs and government support, though key financial ratios are currently unavailable. Recent news highlights strong institutional interest in nuclear ETFs amid rising energy demands.
Outlook is cautiously optimistic given structural tailwinds for nuclear energy, but risks include regulatory shifts and uranium price volatility. The current bearish technical setup may present a buying opportunity if support levels hold, though investors should monitor earnings and expense ratios closely for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
